Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy

Chronic Hepatitis B Virus Infection Clinical Trial

Official title:

An, Open-label, Multicenter, Randomized, Active Control Study, Comparing P1101 Monotherapy to Entecavir Monotherapy in Patients With HBeAg-negative Chronic Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05494528
• Other study ID #: 202003098MIPD
• Secondary ID: A18-I02
• Status: Recruiting
• Phase: N/A
• Start date: May 4, 2021
• Est. completion date: December 30, 2024

Study information

• Verified date: March 2022
• Source: National Taiwan University Hospital
• Contact: Chun-Jen Liu
• Phone: 886-2-23123456
• Email: cjliu[@]ntu.edu.tw
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, multicenter, randomized, active control study, comparing P1101 monotherapy to entecavir monotherapy in patients with HBeAg-negative chronic hepatitis B under long-term nucleos(t)ide analogue therapy.

Description:

Eligible patients will be randomized in a 2:1 ratio (P1101 monotherapy vs. Entecavir monotherapy) using a computer-generated permuted block randomization scheme.

Subjects will be treated with 450 µg of P1101 every two weeks or with 0.5 mg of Entecavir monotherapy once per day. Primary endpoint will be evaluated at week 48. Subjects will receive treatment with a total duration of 72 weeks. The follow-up (treatment-free) period is 24 weeks following completion of treatment. Switch from the other nucleos(t)ide analogue therapy to entecavir will occur at week 0 (Randomization), while the dose of Entecavir will be 0.5 mg.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: December 30, 2024
• Est. primary completion date: December 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 75 Years

Eligibility

Inclusion Criteria:

• Adults with age 20-75 years old; Subjects who are over 70 years of age must be in generally good health;

• Confirmed diagnosis of chronic hepatitis B (CHB) virus infection: with positive HBsAg ? 6 months prior to the study entry;

• Quantitative HBsAg level < 1,500 IU/ml at screening;

• Confirmed HBeAg (-) at screening;

• Stable disease: ALT < 3 x upper limit of normal (ULN), total bilirubin < 1.5 × ULN (except in Gilbert syndrome) and direct bilirubin < ULN at screening, serum HBV DNA < 50 IU/mL for ? 1 year prior to study entry;

• Stable treatment with nucleos(t)ide regimen (adefovir, entecavir, tenofovir or one of the following combinations: entecavir/adefovir or entecavir/tenofovir) for at least 2 years prior to study entry;

• Interferon treatment naïve;

• Normal fundoscopic examination by ophthalmologist at screening; defined as no significant or major fundoscopic findings including but not limited to retinal exudates, hemorrhage, detachment, neovascularization, papilloedema, optic atrophy, microaneurysms and macular changes;

• Be able to attend all scheduled visits and to comply with all study procedures;

• Be able to provide written informed consent.

Exclusion Criteria:

• HBeAg-positive chronic hepatitis B;

• Documented history of drug resistance to any nucleoside/ nucleotide analogue;

• History of treatment with lamivudine or telbivudine prior to the study entry;

• Clinically significant abnormalities, other than HBV infection, based upon the results of a medical history, physical examination, vital signs, and a 12-lead electrocardiogram (ECG) at screening as determined by the investigator;

• Other form of significant chronic liver disease apart from chronic hepatitis B infection; Severe steatohepatitis by ultrasound or other examinations at the discretion of investigators;

• Liver cirrhosis;

• Known positive for anti-HIV;

• Positive for anti-hepatitis C virus(HCV), Subject could be enrolled if no HCV RNA detected within 1 year;

• Co-infection with hepatitis D;

• One of clinically significant abnormal laboratory test result at screening: white blood cell (WBC) < 3,000/mm^3, absolute neutrophil count (ANC) < 1500/mm^3, Hgb < 10g/dL, platelet < 90,000/mm^3, estimated Glomerular filtration rate < 60 mL/min;

• History of significant alcohol or illicit drug abuse within six months prior to the screening visit (alcohol consumption of more than fourteen units of alcohol per week [1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]) or refusal to abstain from illicit drugs and minimize alcohol consumption throughout the study;

• History of severe allergic or hypersensitivity reactions (e.g bronchospasm, angioedema), asthma, or anaphylaxis

• Therapy with any systemic anti-viral treatment (except for treatment for HBV), anti-neoplastic, immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) and immunosuppressants within 1 month (3 months for those with long elimination half-lives) prior to the first dose of study drug;

• Use of an investigational drug within the last 4 weeks;

• Any history or presence of poorly controlled or clinically significant medical conditions that are not suitable to receive interferon-based treatment, at the discretion of the investigator: major psychiatric (including but not limited to those with severe depression, severe bipolar disorder, schizophrenia, suicidal ideation or history of suicidal attempt),neurological, cardiovascular (e.g. uncontrolled hypertension), pulmonary (including but not limited to chronic obstructive lung disease), hematological, immunologic, endocrine, metabolic (e.g. diabetes mellitus with HbA1C > 8.0%), autoimmune disease, thyroid or other uncontrolled systemic disease, coagulation disorders or blood dyscrasias;

• A depot injection or an implant of any drug within 3 months prior to administration of study medication, other than contraception or hyaluronic acid injections in joints for osteoarthritis;

• History of solid organ transplantation;

• History of malignancy diagnosed or treated within 5 years prior to screening (except for recent localized treatment of squamous or noninvasive basal cell skin cancers; cervical carcinoma in situ), cancer survivors not on maintenance therapy within the past 5 years;

• History of opportunistic infection (e.g., invasive candidiasis or pneumocystis pneumonia)

• Serious localized infection (e.g., cellulitis, abscess) or systemic and life-threatening infection (e.g., septicemia) within the 3 months prior to screening;

• Pregnant subjects. Female subjects or the spouse of male subjects, with child-bearing potential who are unwilling or unable to practice adequate contraception, defined as vasectomy in men, tubal ligation in women, or use of condoms and spermicides, or birth control pills, or intrauterine devices from 4 weeks prior to Day 1 until 90 days after the last dose of study drug.

Related Conditions & MeSH terms

• Chronic Hepatitis B Virus Infection
• Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis B, Chronic
• Hepatitis, Chronic
• Herpesviridae Infections

Intervention

Drug:
• Ropeginterferon alfa-2b
Ropeginterferon alfa-2b 450 µg subcutaneous injection every two weeks
• Entecavir
Entecavir 0.5 mg once per day

Locations

Country	Name	City	State
Taiwan	Kaohsiung Medical University Chung-Ho Memorial Hospital	Kaohsiung
Taiwan	China Medical University Hospital	Taichung
Taiwan	National Taiwan University Hospital	Taipei
Taiwan	Taipei Medical University Hospital	Taipei
Taiwan	Taipei Veterans General Hospital	Taipei

Sponsors (2)

Lead Sponsor	Collaborator
National Taiwan University Hospital	PharmaEssentia

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Undetectable HBsAg	HBsAg loss at week 48	Week 48
Secondary	Undetectable HBsAg	HBsAg loss at weeks 72 and 96	weeks 72 and 96
Secondary	HBsAg level	HBsAg reduction > 1 log from baseline to weeks 12, 24, 48, 72 and 96	weeks 12, 24, 48, 72 and 96
Secondary	HBsAg and anti-HBs level	HBsAg seroconversion at weeks 48, 72 and 96	weeks 48, 72 and 96
Secondary	HBsAg level	Mean HBsAg decline from baseline to weeks 12, 24, 48, 72, and 96	weeks 12, 24, 48, 72, and 96
Secondary	Reappearance of HBsAg	HBsAg seroreversion at weeks 72 and 96	weeks 72 and 96
Secondary	HBV DNA level	Percentage of subjects with HBV DNA > 2,000 IU/ml at week 96	week 96
Secondary	HBV DNA and alanine aminotransferase (ALT) level	Percentage of subjects with HBV DNA > 2,000 IU/ml and ALT > 2x ULN at week 96	week 96
Secondary	Sustained suppression of HBV DNA	Sustained suppression of HBV DNA less than the lower limit of qualification at week 96.	week 96
Secondary	HBeAg level	To compare the proportion of HBeAg seroreversion and seroconversion at weeks 72 and 96 across treatment arms.	weeks 72 and 96